Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden.
Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
Ultrasound Obstet Gynecol. 2022 Jan;59(1):100-106. doi: 10.1002/uog.24769.
To compare the reproductive outcome after early miscarriage between women managed expectantly and those treated with vaginal misoprostol.
This study was a planned secondary analysis of data collected prospectively in a randomized controlled trial comparing expectant management with vaginal misoprostol treatment (single dose of 800 µg) in women with early embryonic or anembryonic miscarriage and vaginal bleeding. The outcome measures were the number of women with a clinical pregnancy conceived within 14 months after complete miscarriage and the outcome of these pregnancies in terms of live birth, miscarriage, ectopic pregnancy and legal termination of pregnancy. The participants replied to a questionnaire sent by post covering their reproductive history ≤ 14 months after the index miscarriage was complete. Supplementary information and data for women who did not return their questionnaire were retrieved from medical records.
Of 94 women randomized to misoprostol treatment and 95 allocated to expectant management, 94 and 90 women, respectively, were included for analysis. Information on reproductive outcome was available for 89/94 (95%) and 83/90 (92%) women, respectively. Complete miscarriage without surgical evacuation was achieved within 31 days in 85% (76/89) of the women in the misoprostol group and in 65% (54/83) of those managed expectantly. The proportion of women treated with surgical evacuation was 33% (27/83) in the expectant-management group vs 12% (11/89) in the misoprostol group. At 14 months after the index miscarriage was complete, 75% (67/89) of women treated with misoprostol and 75% (62/83) of those managed expectantly had achieved at least one clinical pregnancy, while 40% (36/89) and 35% (29/83), respectively, had had at least one live birth (mean difference, 5.5% (95% CI, -9.7 to 20.3%)). When considering the outcome of all pregnancies conceived within 14 months after the index miscarriage was complete, 63% (56/89) of women in the misoprostol group and 55% (46/83) of those in the expectant-management group delivered a live baby after a pregnancy (mean difference, 7.5% (95% CI, -7.9 to 22.4%)).
Women with early miscarriage can be reassured that fertility is similar after misoprostol treatment and expectant management. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
比较期待治疗与阴道米索前列醇治疗早期流产后妊娠结局。
这是一项前瞻性随机对照试验的二次分析计划,该试验比较了期待治疗与阴道米索前列醇治疗(单剂量 800μg)在有早期胚胎或无胚胎流产和阴道出血的妇女中的疗效。主要结局是在完全流产后 14 个月内有临床妊娠的妇女数量,以及这些妊娠的活产、流产、异位妊娠和合法终止妊娠的结局。参与者通过邮寄问卷回复了他们的生殖史,这些问卷涵盖了完全流产后≤14 个月的情况。对于未回复问卷的妇女,从病历中检索了补充信息和数据。
94 例随机分配至米索前列醇治疗组和 95 例期待治疗组的妇女中,分别有 94 例和 90 例妇女纳入分析。分别有 89/94(95%)和 83/90(92%)例妇女获得了生殖结局信息。米索前列醇组 85%(76/89)的妇女和期待治疗组 65%(54/83)的妇女在 31 天内成功实现完全流产而无需手术清宫。期待治疗组需手术清宫的比例为 33%(27/83),米索前列醇组为 12%(11/89)。在完全流产后 14 个月,米索前列醇治疗组 75%(67/89)和期待治疗组 75%(62/83)的妇女至少有一次临床妊娠,而分别有 40%(36/89)和 35%(29/83)的妇女至少有一次活产(平均差异,5.5%(95%CI,-9.7 至 20.3%))。考虑到完全流产后 14 个月内所有妊娠的结局,米索前列醇组 63%(56/89)和期待治疗组 55%(46/83)的妇女在妊娠后分娩了活产儿(平均差异,7.5%(95%CI,-7.9 至 22.4%))。
对于早期流产的妇女,可以放心,米索前列醇治疗和期待治疗后生育能力相似。© 2021 作者。超声在妇产科由 John Wiley & Sons Ltd 出版代表国际妇产科超声学会。